Latest Mergers And Acquisitions News

Everest Metals Corporation Ltd reported a cautious cash flow update for Q2 2025, highlighting ongoing exploration costs and a funding runway of just under two quarters. The company has completed bulk sampling at its Revere Gold Project but faces continued negative operating cash flows.

Peel Mining Limited has completed key drilling and commenced metallurgical testing at Wagga Tank, while advancing exploration and joint venture activities at Curnamona, maintaining a solid cash position of $1.4 million.

Red Hill Minerals reported robust royalty revenues and exploration progress in the June 2025 quarter, underpinned by strong iron ore shipments and strategic royalty acquisitions. The company’s solid cash position and advancing drill programs position it well for growth.

NEXION Group Ltd has exited a major transaction, sold its Perth data centre, and relaunched its AI-focused subsidiary, positioning itself for renewed growth and ASX reinstatement.

ImpediMed Limited reported a record quarter for its SOZO device sales with $6.3 million in contracts, supported by expanded US reimbursement coverage and new funding. Despite stable revenue, the company’s cost-cutting and strategic moves position it well for growth in FY26.

Island Pharmaceuticals has completed its acquisition of the broad-spectrum antiviral Galidesivir ahead of schedule, setting sights on expedited FDA approval leveraging the Animal Rule.

Estrella Resources has made significant strides in its maiden manganese drilling campaign in Timor-Leste, confirming high-grade mineralisation and advancing a major limestone marketing agreement with an Indonesian partner.

Knosys Limited sustains a robust $9.8 million Annual Recurring Revenue, extends its ANZ Bank contract, and accelerates AI-driven library technology development with promising early market feedback.

Black Dragon Gold progresses its Salave Gold Project’s strategic investment application amid positive community support and reports a stable cash position at quarter-end.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology candidate, completed FDA IND transfer, and plans to launch phase II trials in 2026. The company also reported a solid cash position and issued loyalty options to shareholders.

Dubber Corporation Limited has achieved underlying operating cashflow breakeven for the first time in its history in Q4 FY25, despite the looming impact of a major contract non-renewal. The company plans to offset margin losses through aggressive cost savings and revenue growth in FY26.

Nex Metals Explorations has moved closer to finalising a joint project agreement for its Kookynie Tailings Project while navigating leadership changes and securing fresh capital to fund growth.